Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...
The results of the Precision-T Phase 3 study of investigational allogeneic T-cell immunotherapy, Orca-T, were published in the journal Blood.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback